141 related articles for article (PubMed ID: 27330661)
41. Could serum S100B be a predictor of neuronal damage and clinical poor outcomes associated with the use of synthetic cannabinoids? S100B to predict neuronal damage of SC in the ED.
Yilmaz S; Karakayali O; Kale E; Akdogan A
Am J Emerg Med; 2018 Mar; 36(3):435-441. PubMed ID: 28867154
[TBL] [Abstract][Full Text] [Related]
42. A Curious Case of Inhalation Fever Caused by Synthetic Cannabinoid.
Chinnadurai T; Shrestha S; Ayinla R
Am J Case Rep; 2016 Jun; 17():379-83. PubMed ID: 27262587
[TBL] [Abstract][Full Text] [Related]
43. Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice.
Wilson CD; Zheng F; Fantegrossi WE
Psychopharmacology (Berl); 2022 Oct; 239(10):3237-3248. PubMed ID: 35933518
[TBL] [Abstract][Full Text] [Related]
44. Psychotic Disorders in Patients Who Use Synthetic Cannabinoids.
Skryabin VY; Vinnikova MA
J Psychiatr Pract; 2019 Nov; 25(6):485-490. PubMed ID: 31821228
[TBL] [Abstract][Full Text] [Related]
45. Hyperthermia and Severe Rhabdomyolysis From Synthetic Cannabinoids Am J Emerg Med 2016;34:121.e1-2. Doi: 10.1016/j.Ajem.2015.05.052. Epub 2015 Jun 12.
Su M; Laskowski L; Hoffman RS
Am J Emerg Med; 2016 Aug; 34(8):1690. PubMed ID: 27231136
[No Abstract] [Full Text] [Related]
46. Ecstasy intoxication as an unusual cause of epileptic seizures in young children.
Pauwels S; Lemmens F; Eerdekens K; Penders J; Poesen K; Desmet K; Vermeersch P
Eur J Pediatr; 2013 Nov; 172(11):1547-50. PubMed ID: 23828132
[TBL] [Abstract][Full Text] [Related]
47. 'Crazy Monkey' poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid.
Gugelmann H; Gerona R; Li C; Tsutaoka B; Olson KR; Lung D
Clin Toxicol (Phila); 2014 Jul; 52(6):635-8. PubMed ID: 24905571
[TBL] [Abstract][Full Text] [Related]
48. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.
McQuade D; Hudson S; Dargan PI; Wood DM
Eur J Clin Pharmacol; 2013 Mar; 69(3):373-6. PubMed ID: 22936123
[TBL] [Abstract][Full Text] [Related]
49. The other side of the leaf: Seizures associated with synthetic cannabinoid use.
Gounder K; Dunuwille J; Dunne J; Lee J; Silbert P; Lawn N
Epilepsy Behav; 2020 Mar; 104(Pt A):106901. PubMed ID: 31958643
[TBL] [Abstract][Full Text] [Related]
50. Acute kidney injury associated with smoking synthetic cannabinoid.
Buser GL; Gerona RR; Horowitz BZ; Vian KP; Troxell ML; Hendrickson RG; Houghton DC; Rozansky D; Su SW; Leman RF
Clin Toxicol (Phila); 2014 Aug; 52(7):664-73. PubMed ID: 25089722
[TBL] [Abstract][Full Text] [Related]
51. Clinical presentation of intoxication due to synthetic cannabinoids.
Cohen J; Morrison S; Greenberg J; Saidinejad M
Pediatrics; 2012 Apr; 129(4):e1064-7. PubMed ID: 22430444
[TBL] [Abstract][Full Text] [Related]
52. Synthetic Cannabinoid Exposure in Adolescents Presenting for Emergency Care.
Gilley M; Brent J; Calello DP; Wax P; Finkelstein Y;
Pediatr Emerg Care; 2021 Jan; 37(1):e13-e16. PubMed ID: 29538266
[TBL] [Abstract][Full Text] [Related]
53. Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA.
Angerer V; Jacobi S; Franz F; Auwärter V; Pietsch J
Forensic Sci Int; 2017 Dec; 281():e9-e15. PubMed ID: 29133010
[TBL] [Abstract][Full Text] [Related]
54. Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds.
Sznitman SR; Pinsky-Talbi L; Salameh M; Moed T; Bentur Y
Int J Drug Policy; 2020 Mar; 77():102711. PubMed ID: 32126489
[TBL] [Abstract][Full Text] [Related]
55. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
[TBL] [Abstract][Full Text] [Related]
56. Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA.
Adamowicz P; Meissner E; Maślanka M
Clin Toxicol (Phila); 2019 Nov; 57(11):1103-1108. PubMed ID: 30806094
[No Abstract] [Full Text] [Related]
57. Notes from the field: Severe illness associated with synthetic cannabinoid use - Brunswick, Georgia, 2013.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2013 Nov; 62(46):939. PubMed ID: 24257204
[TBL] [Abstract][Full Text] [Related]
58. Synthetic cannabinoid drug use as a cause or contributory cause of death.
Labay LM; Caruso JL; Gilson TP; Phipps RJ; Knight LD; Lemos NP; McIntyre IM; Stoppacher R; Tormos LM; Wiens AL; Williams E; Logan BK
Forensic Sci Int; 2016 Mar; 260():31-39. PubMed ID: 26795398
[TBL] [Abstract][Full Text] [Related]
59. Synthetic legal intoxicating drugs: the emerging 'incense' and 'bath salt' phenomenon.
Jerry J; Collins G; Streem D
Cleve Clin J Med; 2012 Apr; 79(4):258-64. PubMed ID: 22473725
[TBL] [Abstract][Full Text] [Related]
60. Bilateral multiple exudative retinal detachments and macular edema in a patient diagnosed with synthetic cannabinoid (Bonzai) intoxication.
Kırgız A; Kaldırım H
Int Ophthalmol; 2019 Jan; 39(1):237-241. PubMed ID: 29275529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
